Company

Delcath Systems, Inc.

Headquarters: New York, NY, United States

Employees: 33

CEO: Mr. Gerard J. Michel

NASDAQ: DCTH -2.83%

Market Cap

$221.2 Million

USD as of July 1, 2024

Market Cap History

Delcath Systems, Inc. market capitalization over time

Evolution of Delcath Systems, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Delcath Systems, Inc.

Detailed Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Delcath Systems, Inc. has the following listings and related stock indices.


Stock: NASDAQ: DCTH wb_incandescent

Stock: OTC: DCTH wb_incandescent

Product & Services

Pharmaceutical and medical device company focused on oncology

Details

Headquarters:

1633 Broadway

22nd Floor Suite C

New York, NY 10019

United States

Phone: 212 489 2100

Fax: 212 489 2102